CKD Clinical Trial
Official title:
Washed Microbiota Transplantation (WMT) for Chronic Kidney Disease (CKD): a Open Label, Multicenter Trial
Wahsed microbiota transplantation (WMT) is a novel and promising therapeutic method for Chronic Kidney Disease (CKD). This clinical trail aims to evaluate the efficacy and safety of WMT in the treatment of CKD.
Although the therapeutic methods progress, numerous patients with Chronic Kidney Disease (CKD) can not avoid the clinical outcome of end-stage renal disease. CKD still needs novel treatment to significantly improve the survival quality of the patients. Gut microbiota has been verified to have relation with immunity. Immunity plays a role in many chronic kidney disease, such as IgA nephropathy, membranous nephropathy and so on. Fecal microbiota transplantation (FMT) is a novel, safe, convenient therapeutic treatment which transplant gut microbiota from donor to patient to rebuild a gut microecology. This study aims to evaluate the efficacy and safety of FMT in CKD patients. Patients in this study will undergo three times WMT. The primary outcome measure was the clinical remission efficacy rate in the CKD patients. The secondary outcome measure was the safety of WMT in CKD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03277911 -
Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases
|
N/A | |
| Active, not recruiting |
NCT04008810 -
Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
|
||
| Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
| Active, not recruiting |
NCT05356325 -
FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.
|
||
| Completed |
NCT04709120 -
Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection
|
||
| Not yet recruiting |
NCT04491669 -
Screening of Gastrointestinal Tract Bleeding Causes Among Chronic Renal Failure Patients
|
||
| Terminated |
NCT03277183 -
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
|
Phase 4 | |
| Enrolling by invitation |
NCT04491227 -
Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|
||
| Recruiting |
NCT06279429 -
Sucrosomial Iron on Insomnia in Non-dialysis Chronic Kidney Disease Patients With Iron Deficiency Anemia
|
N/A | |
| Recruiting |
NCT03501745 -
Smart-CKD/BP Study
|
N/A | |
| Recruiting |
NCT04708743 -
The Tongue Features Associated With Chronic Kidney Disease
|
||
| Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
| Completed |
NCT04119570 -
CKD Report Card Pilot Trial
|
N/A | |
| Completed |
NCT06374043 -
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
|
Phase 4 | |
| Not yet recruiting |
NCT06094920 -
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
|
Phase 4 | |
| Recruiting |
NCT04819217 -
Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease
|
N/A | |
| Completed |
NCT05970094 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
| Withdrawn |
NCT04782297 -
Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)
|
||
| Recruiting |
NCT05784389 -
Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5
|
N/A | |
| Recruiting |
NCT04630132 -
Renal Ageing-sarcopenia Network
|